Kalohexis Exits Stealth with Melanocortin-Based Obesity and Cachexia Pipeline
Event summary
- Kalohexis spun out from Endevica Bio with a focus on melanocortin system therapeutics for obesity and metabolic diseases.
- Lead candidate 710GO, an oral dual MC3R/MC4R agonist, showed 11.7% weight reduction in obese non-human primates without lean body mass loss or gastrointestinal side effects.
- Phase 2 trial of mifomelatide for cancer cachexia is ongoing, with Phase 1 showing modest weight gain and hunger increase compared to placebo.
The big picture
Kalohexis' emergence highlights the growing interest in targeting the melanocortin system for metabolic diseases, offering a potential alternative to GLP-1 agonists. The company's focus on durable weight loss without lean body mass loss or gastrointestinal side effects could position it as a key player in the obesity treatment market. With ongoing Phase 2 trials and plans for Phase 1 initiation of its lead candidate, Kalohexis is poised to compete in a space dominated by established players like Novo Nordisk and Eli Lilly.
What we're watching
- Clinical Validation
- Whether 710GO can replicate preclinical results in human trials, particularly regarding durable weight loss and side effect profile.
- Market Differentiation
- How Kalohexis positions its melanocortin-based approach against existing GLP-1 receptor agonists in the obesity market.
- Pipeline Expansion
- The pace at which Kalohexis advances additional indications beyond obesity and cachexia, such as type 2 diabetes and NASH.
Our editorial coverage:
Related topics